Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Holding CSTL?
Track your performance easily
CSTL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.07 - $32.53
Previous Close$30.53
Volume256.57K
Average Volume (3M)418.88K
Market Cap
$856.79M
Enterprise Value$612.29M
Total Cash (Recent Filing)$259.70M
Total Debt (Recent Filing)$25.19M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 11, 2024EPS Estimate
-$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding27,736,760
10 Day Avg. Volume336,932
30 Day Avg. Volume418,882
Standard Deviation0.17
R-Squared0.09
Alpha0.00509
Financial Highlights & Ratios
Price to Book (P/B)2.00
Price to Sales (P/S)2.93
Price to Cash Flow (P/CF)8.80
P/FCF Ratio11.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.13
Enterprise Value/Gross Profit3.50
Enterprise Value/Ebitda78.98
Forecast
1Y Price Target
$37.17Price Target Upside20.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Castle Biosciences News
PremiumCompany Announcements
Castle Biosciences Unveils Strategy in Management Presentations
Bulls Say, Bears Say
Bulls Say
Guidance And OutlookCastle Biosciences raised its annual revenue guidance to $275-300 million, reflecting confidence in sustained growth and strong market performance.
ProfitabilityCastle Biosciences achieved a net income of $8.9 million, defying expectations of a net loss.
Revenue GrowthCastle Biosciences reported 2Q revenue of $87 million, significantly beating estimates and showing robust performance.
Bears Say
Regulatory And Reimbursement RisksReimbursement risk and government regulation are significant factors impacting the company.
Reimbursement DecisionA non-coverage decision from Novitas is unlikely to be viewed positively.
Technological And Competitive RisksThe company faces risks from competition and technological advances.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $12.07 and its highest was $32.53 in the past 12 months.
What is Castle Biosciences’s market cap?
Currently, no data Available
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Nov 11, 2024 which is in 52 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on Aug 05, 2024. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of -$0.269 by $0.579.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -$0.03.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 27,736,760 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of $0.31 in its last earnings report, beating expectations of -$0.269. Following the earnings report the stock price went up 13.959%.
Which hedge fund is a major shareholder of Castle Biosciences?
Among the largest hedge funds holding Castle Biosciences’s share is Deerfield Management Company, LP. It holds Castle Biosciences’s shares valued at 19M.
---
Castle Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.17 (20.33% Upside)
$37.17 (20.33% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 46.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.05%
12-Months-Change
Fundamentals
Return on Equity
-0.77%
Trailing 12-Months
Asset Growth
14.55%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
---
CSTL Company Deck
---
CSTL Earnings Call
Q2 2024
0:00 / 0:00
---
CSTL Stock 12 Month Forecast
Average Price Target
$37.17
▲(20.33% Upside)
Technical Analysis
Best Analysts Covering CSTL
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+27.16%
reiterated a buy rating last month
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +27.16% per trade.
---